文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

超保护性通气与无呼吸通气在体外膜氧合治疗的急性呼吸窘迫综合征患者中的比较:一项生理学研究

Ultraprotective versus apneic ventilation in acute respiratory distress syndrome patients with extracorporeal membrane oxygenation: a physiological study.
PubMed 文献 · J Intensive Care · 2022-03-07
一句话结论在ECMO治疗的重度ARDS患者中,超保护性通气较无呼吸通气改善氧合但增加应力、应变和机械功率;作者认为无呼吸通气可考虑作为ECMO初始阶段的选项之一以促进肺休息。

该前瞻性单中心生理学研究纳入24例接受ECMO治疗的重度ARDS患者,先后应用超保护性通气(潮气量3 ml/kg预测体重)和无呼吸通气(仅应用PEEP),FiO2分别为21%、50%和90%。主要终点为通气策略对氧合和氧输送的影响。结果显示超保护性通气较无呼吸通气改善氧合(FiO2为50%和90%时动脉血氧分压P<0.001)并降低心输出量,两种策略在各自FiO2下均维持氧输送;超保护性通气增加驱动压、应力、应变、机械功率,并在非依赖肺区诱导更多复张。作者认为无呼吸通气可考虑作为重度ARDS患者ECMO初始阶段的选项之一,以促进肺休息并预防呼吸机相关肺损伤。

要点

  • 在ECMO治疗的重度ARDS患者中,超保护性通气(潮气量3 ml/kg预测体重)较无呼吸通气改善氧合,FiO2为50%和90%时动脉血氧分压P<0.001。
  • 超保护性通气较无呼吸通气降低心输出量,但两种策略在FiO2为21%、50%和90%时均维持氧输送。
  • 超保护性通气较无呼吸通气增加驱动压、应力、应变和机械功率,并在非依赖肺区诱导额外复张。
  • 作者认为,无呼吸通气可考虑作为重度ARDS患者ECMO初始阶段的选项之一,以促进肺休息并预防呼吸机相关肺损伤。

适用人群与场景

  • 接受ECMO治疗的24例重度ARDS患者,来自前瞻性单中心生理学研究。

处置流程与药物剂量

  • 超保护性通气:潮气量3 ml/kg预测体重,FiO2分别为21%、50%和90%。
  • 无呼吸通气:仅应用PEEP,FiO2与超保护性通气时类似(21%、50%和90%)。

研究设计与关键结果

  • 前瞻性单中心生理学研究,纳入24例接受ECMO治疗的重度ARDS患者,比较超保护性通气(潮气量3 ml/kg预测体重)与无呼吸通气(仅应用PEEP)在FiO2为21%、50%和90%时的效应。
  • 主要终点:超保护性通气较无呼吸通气改善氧合,FiO2为50%和90%时动脉血氧分压P<0.001。
  • 超保护性通气较无呼吸通气降低心输出量;两种通气策略在各自FiO2下均维持氧输送。
  • 超保护性通气较无呼吸通气增加驱动压、应力、应变和机械功率,并在非依赖肺区诱导额外复张。

证据类型、等级与局限

  • 证据类型:前瞻性单中心生理学研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,无呼吸通气可考虑作为重度ARDS患者ECMO初始阶段的选项之一,以促进肺休息并预防呼吸机相关肺损伤。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Even an ultraprotective ventilation strategy in severe acute respiratory distress syndrome (ARDS) patients treated with extracorporeal membrane oxygenation (ECMO) might induce ventilator-induced lung injury and apneic ventilation with the sole application of positive end-expiratory pressure may, therefore, be an alternative ventilation strategy. We, therefore, compared the effects of ultraprotective ventilation with apneic ventilation on oxygenation, oxygen delivery, respiratory system mechanics, hemodynamics, strain, air distribution and recruitment of the lung parenchyma in ARDS patients with ECMO.

METHODS: In a prospective, monocentric physiological study, 24 patients with severe ARDS managed with ECMO were ventilated using ultraprotective ventilation (tidal volume 3 ml/kg of predicted body weight) with a fraction of inspired oxygen (FiO2) of 21%, 50% and 90%. Patients were then treated with apneic ventilation with analogous FiO2. The primary endpoint was the effect of the ventilation strategy on oxygenation and oxygen delivery. The secondary endpoints were mechanical power, stress, regional air distribution, lung recruitment and the resulting strain, evaluated by chest computed tomography, associated with the application of PEEP (apneic ventilation) and/or low VT (ultraprotective ventilation).

RESULTS: Protective ventilation, compared to apneic ventilation, improved oxygenation (arterial partial pressure of oxygen, p < 0.001 with FiO2 of 50% and 90%) and reduced cardiac output. Both ventilation strategies preserved oxygen delivery independent of the FiO2. Protective ventilation increased driving pressure, stress, strain, mechanical power, as well as induced additional recruitment in the non-dependent lung compared to apneic ventilation.

CONCLUSIONS: In patients with severe ARDS managed with ECMO, ultraprotective ventilation compared to apneic ventilation improved oxygenation, but increased stress, strain, and mechanical power. Apneic ventilation might be considered as one of the options in the initial phase of ECMO treatment in severe ARDS patients to facilitate lung rest and prevent ventilator-induced lung injury.

TRIAL REGISTRATION: German Clinical Trials Register (DRKS00013967). Registered 02/09/2018. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00013967 .

来源:J Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Graf PT, Boesing C, Brumm I, et al. Ultraprotective versus apneic ventilation in acute respiratory distress syndrome patients with extracorporeal membrane oxygenation: a physiological study. J Intensive Care. 2022. PMID: 35256012. doi:10.1186/s40560-022-00604-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。